Public Citizen advised Amazon's acquisition of One Medical should be rejected if Amazon does not commit to robust, legally binding safeguards in a letter sent today to authorized U.S decision-makers.
Article updated Aug. 4 with comment from an Amazon spokesperson.
Public Citizen advised Amazon's proposed acquisition of healthcare provider, One Medical, should be rejected in a letter sent the Centers for Medicare and Medicaid Services, the Federal Trade Commission, the U.S. Department of Justice, and leaders in Congress.
The non-profit consumer advocacy group that defends democracy and works to ensure government works for the people, wrote today that the merger should be investigated or "rejecteted unless Amazon commits to robust, legally binding safeguards that protect consumers, competition, and the integrity of the health care system."
Public Citizen raised the following concerns:
According to a statement by Robert Weissman, president of Public Citizen, in the release, the American healthcare system is broken, but Amazon’s entry as a major healthcare provider could make it worse.
“We may get marketing instead of medicine, data harvesting instead of privacy protections, robotic care instead of bedside manner, and more healthcare disparity instead of more quality," Weissman said. "The problem of American healthcare can be summed up as too much greed and not enough patient care. The Amazon acquisition of One Medical will only deepen that problem.”
An Amazon spokesperson commented on the statement regarding the safety of One Medical's member information.
“As required by law, Amazon will never share One Medical customers’ personal health information outside of One Medical for advertising or marketing purposes of other Amazon products and services without clear permission from the customer," wrote the spokesperson. “Should the deal close, One Medical customers' HIPAA Protected Health Information will be handled separately from all other Amazon businesses, as required by law.”
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More